Newsroom

A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center. 

Results from the Phase II umbrella HUDSON study, published today in Nature Medicine, demonstrated that the anti PD-L1 antibody...